Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
← catalyst calendarSponsored by Exelixis (industry) · EXEL — their whole pipeline →. With Arcus Biosciences, Inc..
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
25actual
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was terminated prior to starting the Phase 2 portion due to a business decision.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-25 | actual | When the study began enrolling |
| Primary completion | 2025-05-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-12 | actual | The whole study's end, after follow-up |
| First posted | 2024-01-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Interventions
- Drug: zanzalintinib — also filed as XL092
- Drug: AB521
- Biological: Nivolumab — also filed as OPDIVO®
Primary outcomes
what the primary-completion date above is the date OFDose-finding Stage: Number of participants with dose-limiting toxicities (DLTs)
measured Up to 24 months
Expansion Stage: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the Investigator
measured Up to 24 months
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed